ATLASProtagonist Therapeutics (PTGX) earnings date: Nov 5, 2026
Protagonist Therapeutics (PTGX) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 5, 2026, after the close. Analysts expect EPS of $2.58.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on PTGX
| Last price | $144.85 (+0.4%) |
|---|---|
| Normal 1-day range (±1σ) | ±2.3% |
| Earnings beat history | Beat the EPS estimate in 3 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Protagonist Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Protagonist Therapeutics reports on Nov 5, 2026. One email the day before, with ATLAS’s read on Protagonist Therapeutics. You can switch it off at any time.
Alert me before PTGX reportsFree to start. Creating an account takes under a minute.
PTGX earnings at a glance
| Next report (confirmed) | Thu, Nov 5, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | $2.58 |
| Last report | Aug 5, 2026 · Beat |
| Beat rate (last 5 reports) | 3 of 5 (60%) |
| Average EPS surprise | +27.9% |
| Average move around a report | ±3.5% (last 5) |
| Sector | Healthcare · Biotechnology |
Protagonist Therapeutics earnings history: last 5 reports
Protagonist Therapeutics last reported on Aug 5, 2026: EPS of $2.29 against an estimate of $1.93 (+18.7% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 5, 2026 | $1.93 | $2.29 | +18.7% | Beat | +7.6% |
| May 21, 2026 | $2.60 | $3.64 | +40.0% | Beat | -1.7% |
| May 5, 2026 | -$0.65 | $0.05 | +107.7% | Beat | +4.5% |
| Feb 25, 2026 | -$0.54 | -$0.69 | -27.8% | Miss | +1.1% |
| Feb 11, 2026 | $2.08 | $2.10 | +1.0% | In line | -2.3% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for PTGX
See the fair value, the probability range and the earnings history of Protagonist Therapeutics on its ATLAS page.
Protagonist Therapeutics (PTGX) stock analysisPlans from €3.99 a month.
Protagonist Therapeutics earnings: frequently asked questions
When does Protagonist Therapeutics (PTGX) report earnings?
Protagonist Therapeutics is scheduled to report on Thursday, November 5, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for PTGX?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is $2.58 per share (USD). Estimates can change before the report.
How often does PTGX beat earnings estimates?
Of its last 5 reports with a recorded result, Protagonist Therapeutics beat the EPS estimate 3 times; the average surprise was +27.9%. Past results do not predict the next one.
How much does PTGX move around earnings?
Over its last 5 reports the stock moved an average of 3.5% (absolute, from the close before the report day to the close after it), and finished higher 3 of 5 times.
Did Protagonist Therapeutics beat earnings estimates last quarter?
Protagonist Therapeutics last reported on Aug 5, 2026: EPS of $2.29 against an estimate of $1.93 (+18.7% surprise), a beat.
How much does PTGX usually move in a day?
On a normal trading day the ATLAS model puts PTGX’s one-day range at about ±2.3%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 5, 2026
Educational information, not investment advice. Disclaimer